Drugs

Jayastu Senapati: Optimal use of Azacytidine Venetoclax in AML Patients in Indian Scenario

Photo taken from Jayastu Senapati/X

May 21, 2024, 04:55

Jayastu Senapati: Optimal use of Azacytidine Venetoclax in AML Patients in Indian Scenario

Jayastu Senapati, Assistant Professor of Leukemia at MD Anderson Cancer Center, shared a post on X:

“Looking forward to discussing the optimal use of Hypomethylating Agent (HMA) – Venetoclax in patients with Acute Myeloid Leukaemia (AML), focussing on Indian/Low and Middle-Income Country (LMIC) settings- May 17, CT 8:30AM (IST 7PM).”

Additional information.
Source: Jayastu Senapati/X

Acute Myeloid Leukaemia cancer Hypomethylating agents (HMA) Jayastu Senapati Low and middle-income countries (LMIC) MD Anderson Cancer Cente OncoDaily Oncology venetoclax

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage